Business Context and Reporting Period
DarioHealth Corp. (DRIO) filed this Form 8-K on July 31, 2020, reporting a private equity offering completed on July 31, 2020. The company, incorporated in Delaware and headquartered in Israel, is an emerging growth company.
Key Financial Metrics and Transaction Details
The filing details a capital raise consisting of two closings:
- First Closing (July 28, 2020): Sale of 2,969,266 shares of Common Stock at $7.47 per share and 824,689 Pre-Funded Warrants at $7.4699 per warrant.
- Second Closing (July 30, 2020): Sale of 31,486 shares of Common Stock at $7.94 per share.
- Total Shares Issued: 3,000,752 shares of Common Stock plus Pre-Funded Warrants for 824,689 shares.
- Transaction Costs:
- Placement Agent (Aegis Capital Corp.): $910,224 cash fee, $617,721 expense allowance, and warrants to purchase 196,193 shares.
- Financial Advisor (Rosario Capital): $481,319 fee.
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity metrics for the reporting period.
Material Changes
The primary material change is the increase in outstanding equity and cash proceeds from the Offering. The transaction price represents the "Minimum Price" pursuant to Nasdaq Rule 5635(d). The company also entered into a Registration Rights Agreement requiring a registration statement for resale within 90 days of the final closing.
Outlook, Risks, and Unusual Items
Unusual Items: The issuance of Pre-Funded Warrants allows investors to purchase shares at a nominal exercise price ($0.0001) but includes beneficial ownership limitations (4.99% or 9.99% cap, extendable to 19.99% with shareholder approval).
Risks and Contingencies: The securities were issued under Section 4(a)(2) and Rule 506(b) exemptions and are not registered under the Securities Act of 1933. They may not be sold in the United States absent registration or an exemption. The Placement Agent was granted a six-month right of first refusal for future U.S. private placements.
Investor Verification Checklist
- Verify the total gross proceeds raised from the Offering by calculating the weighted average of the First and Second Closing prices against the share counts.
- Confirm the dilution impact of the 824,689 Pre-Funded Warrants and the 196,193 Placement Agent Warrants on existing shareholders.
- Review the upcoming periodic report for the full text of the Subscription Agreements and Registration Rights Agreement.
- Check subsequent filings to confirm the filing of the registration statement within the required 90-day window.